These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 27092313

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples.
    Pierog P, Krishna M, Yamniuk A, Chauhan A, DeSilva B.
    J Immunol Methods; 2015 Jan; 416():124-36. PubMed ID: 25462536
    [Abstract] [Full Text] [Related]

  • 4. Epitope characterization of the ADA response directed against a targeted immunocytokine.
    Stubenrauch K, Künzel C, Vogel R, Tuerck D, Schick E, Heinrich J.
    J Pharm Biomed Anal; 2015 Oct 10; 114():296-304. PubMed ID: 26093509
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.
    Hock MB, Thudium KE, Carrasco-Triguero M, Schwabe NF.
    AAPS J; 2015 Jan 10; 17(1):35-43. PubMed ID: 25380723
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A generic anti-drug antibody assay for monoclonal antibody therapeutics with broad dynamic range eliminates the need for titer evaluation in preclinical studies.
    Li H, Foley AR, Shim J, Siradze K, Webb-Vargas Y, Sperinde G, Fischer SK.
    J Pharm Biomed Anal; 2024 Oct 15; 249():116364. PubMed ID: 39047461
    [Abstract] [Full Text] [Related]

  • 8. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA, Andrews PA, Blanset D, Flagella KM, Gorovits B, Lynch CM, Martin PL, Kramer-Stickland K, Thibault S, Warner G.
    Regul Toxicol Pharmacol; 2013 Dec 15; 67(3):382-91. PubMed ID: 24012707
    [Abstract] [Full Text] [Related]

  • 9. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers.
    Liu Y, Reidler H, Pan J, Milunic D, Qin D, Chen D, Vallejo YR, Yin R.
    J Pharmacol Toxicol Methods; 2011 Dec 15; 64(3):238-45. PubMed ID: 21827863
    [Abstract] [Full Text] [Related]

  • 10. Strategy and validation of a nonclinical generic plug-and-play antidrug antibody method for human monoclonal antibody biotherapeutics.
    Polsky R, Gunn G, Reese KJ, Hottenstein CS, Gehman A, Schwartz A, Root D, Concannon A.
    Bioanalysis; 2024 Mar 15; 16(5):277-287. PubMed ID: 38334073
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials.
    Carrasco-Triguero M, Dere RC, Milojic-Blair M, Saad OM, Nazzal D, Hong K, Kaur S.
    Bioanalysis; 2019 Sep 15; 11(17):1555-1568. PubMed ID: 31208199
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the NIDS® rapid assay with ELISA methods in immunogenicity testing of two biotherapeutics.
    Pan J, Small T, Qin D, Li S, Wang L, Chen D, Pauley C, Verch T, Kaplanski C, Bakhtiar R, Vallejo YR, Yin R.
    J Pharmacol Toxicol Methods; 2011 Sep 15; 63(2):150-9. PubMed ID: 20868758
    [Abstract] [Full Text] [Related]

  • 13. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
    Li J, Schantz A, Schwegler M, Shankar G.
    J Pharm Biomed Anal; 2011 Jan 25; 54(2):286-94. PubMed ID: 20869832
    [Abstract] [Full Text] [Related]

  • 14. Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies.
    Wang SJ, Wu ST, Gokemeijer J, Fura A, Krishna M, Morin P, Chen G, Price K, Wang-Iverson D, Olah T, Weiner R, Tymiak A, Jemal M.
    Anal Bioanal Chem; 2012 Jan 25; 402(3):1229-39. PubMed ID: 22130720
    [Abstract] [Full Text] [Related]

  • 15. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B, Wakshull E, Pillutla R, Xu Y, Manning MS, Goyal J.
    J Immunol Methods; 2014 Jun 25; 408():1-12. PubMed ID: 24861938
    [Abstract] [Full Text] [Related]

  • 16. Emerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies.
    Partridge MA, Purushothama S, Elango C, Lu Y.
    J Immunol Res; 2016 Jun 25; 2016():6262383. PubMed ID: 27556048
    [Abstract] [Full Text] [Related]

  • 17. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A, Yeung D, Subramanyam M, Amaravadi L.
    J Immunol Methods; 2011 Feb 28; 365(1-2):38-49. PubMed ID: 21130095
    [Abstract] [Full Text] [Related]

  • 18. An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates.
    Lansita JA, Burke JM, Apgar JF, Mounho-Zamora B.
    Pharm Res; 2015 Nov 28; 32(11):3584-92. PubMed ID: 26108879
    [Abstract] [Full Text] [Related]

  • 19. Generic anti-drug antibody assay with drug tolerance in serum samples from mice exposed to human antibodies.
    Stubenrauch K, Mackeben K, Vogel R, Heinrich J.
    Anal Biochem; 2012 Nov 15; 430(2):193-9. PubMed ID: 22935295
    [Abstract] [Full Text] [Related]

  • 20. Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody-drug conjugate therapeutic.
    Carrasco-Triguero M, Mahood C, Milojic-Blair M, Amaya C, Ruppel J, Hong K, Yi JH, Kaur S.
    Bioanalysis; 2012 Aug 15; 4(16):2013-26. PubMed ID: 22946917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.